Regeneron’s siRNA therapy cemdisiran has received FDA approval and is now marketed as Livsayis for myasthenia gravis. The approval makes it the second new drug approved by the FDA for myasthenia gravis inside a week, tightening competitive dynamics in neuromuscular immunology. The product’s mechanism—RNA interference intended to reduce disease-relevant biology—adds to the growing momentum for RNA-based therapies beyond oncology. Regeneron’s framing of the drug’s regulatory milestone also reflects broader positioning around RNA delivery and manufacturing capabilities. For clinicians, the practical impact will hinge on patient eligibility, dosing logistics, and comparative performance versus existing immunotherapies. For the industry, the approval underscores that regulatory agencies continue to accept mechanistic RNA modality differentiation when clinical endpoints are demonstrated. (Story context: the report ties the approval to a fast sequence of myasthenia gravis authorizations.)
Get the Daily Brief